瓦尔贝纳用于治疗与亨廷顿病相关的胆病
Jorge Patino1, Erin Furr Stimming1, Claudia M Testa2
1Department of Neurology, UTHealth Houston McGovern Medical School, Houston, TX, USA.
Expert opinion on pharmacotherapy
|December 27, 2024
概括
瓦尔贝纳有效治疗亨廷顿病 (HD) 中的胆管病. 与其他治疗方法相比,它的选择性作用可能会减少副作用,尽管成本可能是一个障碍.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 霍乱是亨廷顿病 (HD) 的运动症状,影响日常功能,增加跌倒风险.
- 目前的治疗方法包括FDA批准的膀单胺转运体2 (VMAT2) 抑制剂:四贝纳,二贝纳和瓦尔贝纳.
研究的目的:
- 审查瓦尔贝纳的药理学,疗效,安全性和耐受性,用于治疗HD的胆发病.
- 讨论VMAT2抑制剂相互作用,重点关注valbenazine与常见的HD神经精神病药物.
主要方法:
- 对药理性质的审查. 药理性质的审查.
- 对临床疗效和安全数据的分析.
- 讨论药物相互作用的考虑因素.
主要成果:
- 瓦尔贝纳在治疗胆固醇症方面表现出有效性.
- 它的选择性可能会减轻VMAT1相关的副作用,晚期运动不良,帕金森症和行为变化.
- 高的共同支付成本可能会限制患者的访问.
结论:
- 瓦尔贝纳是一种有效的选择,用于HD的胆发病.
- 需要进一步进行对比试验,以将瓦尔贝纳与其他已批准的VMAT2抑制剂进行比较.
相关概念视频
Parkinson's Disease: Treatment
216
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
216
Alzheimer's Disease: Treatment
162
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
162
Indirect-Acting Cholinergic Agonists: Pharmacological Actions
614
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
614
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
222
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
222
Antiepileptic Drugs: Potassium Channel Activators
143
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
143
Parkinson's Disease: Overview
476
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
476


